The Incubator for Antimicrobial Therapies in Europe, INCATE, aims to support innovators in the early stages of developing therapies in the field of antimicrobial resistance. The German Center for
Why do the gut microbiomes of people from industrialized and non-industrialized regions differ? A study by the research team led by DZIF scientist Prof. Till Strowig of the Helmholtz Centre for
In acute, life-threatening infections, rapidly characterizing the microorganisms in a patient sample can help guide diagnosis and treatment. This is possible by using computational methods known as
According to the World Health Organization (WHO), tuberculosis (TB) affects more than 10 million people and causes over a million deaths each year, making it one of the world’s deadliest infectious
An international working group led by the German Society for Infectious Diseases (DGI) has developed a guideline for personalized phage therapy. Twenty professional organizations, 18 international
The current outbreak of Bundibugyo virus (BDBV) in the Democratic Republic of the Congo highlights the challenges of responding to rare but potentially devastating infectious diseases. Two studies led
The files may be used free of charge for press and media coverage. Commercial use is not permitted. Please credit the copyright holder as indicated.
The DZIF flagship project PANTIPA has reached an important milestone. Following successful preclinical work at the University Hospital Cologne and the Helmholtz Centre for Infection Research, the
The SARS-CoV-2 virus is constantly mutating. As a result, vaccines become less effective and require regular adaptation. This was the case in 2025 with the JN.1 variant. An interdisciplinary team from
Researchers at the University Medical Center Hamburg-Eppendorf (UKE), including several scientists from the German Center for Infection Research (DZIF), have worked with colleagues at the University
A research team from Switzerland and Germany has explored the combined use of phage and fecal microbiota transplantation to treat female patients with recurrent urinary tract infections that do not
